EQS-Adhoc: BB Biotech AG publishes its interim report

Ad hoc announcement pursuant to Art. 53 LR

July 25, 2025

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2025, which covers the results of its business activities for the first six months of 2025.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended June 30, 2025, amounted to CHF 341 mn (gain of CHF 173 mn in H1 2024). In the second quarter a loss of CHF 100 mn (loss of CHF 87 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

The interim report as at June 30, 2025, is available under report.bbbiotech.ch/Q225 or www.bbbiotech.com.

For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, Phone +41 44 267 67 00

Head BB Biotech
Dr. Christian Koch

Head Investor Relations
Rachael Burri*

Investor Relations
Claude Mikkelsen

E-Mail: ir@bbbiotech.com
Phone: +41 44 267 67 05

Media Relations
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

*Start on August 1, 2025

Company profile 
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.